Alector Inc.

**Signal Note: Deerfield initiates $1.6M position in Alector (ALEC)** Deerfield's entry into ALEC likely reflects conviction in the company's neuroinflammation pipeline, particularly AL001 (NLRP3 inhibitor) for frontotemporal dementia and potentially Alzheimer's, where NLRP3 pathway validation has strengthened post-recent clinical data. The timing suggests confidence ahead of anticipated FTD readouts or partnership developments, though the position size ($1.6M) is modest relative to ALEC's market cap, indicating a speculative rather than conviction-scale bet. Watch for clinical updates or collaboration announcements within 6-12 months as near-term catalysts.